Advertisement

Opioid switching and variability in response in pain cancer patients

  • O. Corli
  • A. Roberto
  • N. CorsiEmail author
  • F. Galli
  • M. Pizzuto
Original Article

Abstract

Introduction

Opioid switching is a possible strategy for inadequate analgesia or unmanageable side effects. Its effectiveness ranges from 50 to 90% and is still debated.

Purpose

We analyzed the impact of opioid switching in a cancer pain population treated with strong opioids for pain.

Methods

This is a post hoc analysis from a multicenter, randomized, four-arm, controlled, phase IV clinical trial. Outcome variables included the percentages of switches, the reasons for the switch, the dose changes before and after the switch, depending on the starting opioid, the response in case of inadequate analgesia, and unmanageable toxicity, and the variability of response among and within patients.

Results

We analyzed 498 patients. The opioid was switched in 79 patients (15.9%) 87 times, mainly for uncontrolled pain (52.3%), adverse opioid reactions (22.1%), both of these (4.8%), and dysphagia (20.8%). The reasons for switching varied depending on the starting opioid. Pain reduction was good after 51.45% of switches and control of opioid side effects was good after 43.5%. The relief of opioid-induced toxicity varied among adverse events and within each patient. The daily doses were higher after switching oral opioids and lower after transdermal drugs.

Conclusions

Half of the patients who underwent switching experienced improved relief of pain or amelioration of opioid toxicity. The switch can help in the management of some cases but with many limits and uncertainties.

Keywords

Cancer pain Opioid switching Pain relief Toxicity relief 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Mercadante S, Maddaloni S, Roccella S, Salvaggio L (1992) Predictive factors in advanced cancer pain treated only by analgesics. Pain 50:151–155CrossRefGoogle Scholar
  2. 2.
    Corli O, Floriani I, Roberto A, Montanari M, Galli F, Greco MT, Caraceni A, Kaasa S, Dragani TA, Azzarello G, Luzzani M, Cavanna L, Bandieri E, Gamucci T, Lipari G, di Gregorio R, Valenti D, Reale C, Pavesi L, Iorno V, Crispino C, Pacchioni M, Apolone G, CERP STUDY OF PAIN GROUP (List of collaborators), CERP STUDY OF PAIN GROUP (2016) Are strong opioids equally effective and safe in the treatment of chronic cancer pain? A multicenter randomized phase IV ‘real life’ trial on the variability of response to opioids. Ann Oncol Off J Eur Soc Med Oncol 27:1107–1115CrossRefGoogle Scholar
  3. 3.
    Corli O, Roberto A, Greco MT, Montanari M (2015) Assessing the response to opioids in cancer patients: a methodological proposal and the results. Support Care Cancer 23:1867–1873CrossRefGoogle Scholar
  4. 4.
    Farrar J, Young J, Lamoreaux L et al (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158CrossRefGoogle Scholar
  5. 5.
    Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Strom BL (2000) Defining the clinically important difference in pain outcome measures. Pain 88:287–294CrossRefGoogle Scholar
  6. 6.
    Mercadante S, Bruera E (2016) Opioid switching in cancer pain: from the beginning to nowadays. Crit Rev Oncol Hematol 99:241–248CrossRefGoogle Scholar
  7. 7.
    Kloke M, Rapp M, Bosse B, Kloke O (2000) Toxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single center. Support Care Cancer 8:479–486CrossRefGoogle Scholar
  8. 8.
    Quigley C, Vora RR. Opioid switching to improve pain relief and drug tolerability. Cochrane Database Syst Rev; 2013. DOI:  https://doi.org/10.1002/14651858.CD004847.pub2
  9. 9.
    Benyamin R, Trescot A, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R (2008) Opioid complications and side effects. Pain Physician 11:S105–S120PubMedGoogle Scholar
  10. 10.
    Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D (2012) Adverse effects associated with non-opioid and opioid treatment in patients with chronic pain. Clinical Drug Investigation 32:53–63CrossRefGoogle Scholar
  11. 11.
    Oosten AW, Oldenmenger WH, Mathijssen RHJ (2015) A systematic review of prospective studies reporting adverse events of commonly used opioids for cancer-related pain: a call for the use of standardized outcome measures. J Pain 16:935–946CrossRefGoogle Scholar
  12. 12.
    Mercadante S, Portenoy RK (2001) Opioid poorly-responsive cancer pain. Part 3. Clinical strategies to improve opioid responsiveness. J Pain Symptom Manag 21:338–354CrossRefGoogle Scholar
  13. 13.
    Smith HS, Peppin JF (2014) Toward a systematic approach to opioid rotation. J Pain Res 7:589–608PubMedPubMedCentralGoogle Scholar
  14. 14.
    Mercadante S, Bruera E (2006) Opioid switching: a systematic and critical review. Cancer Treat Rev 32:304–315CrossRefGoogle Scholar
  15. 15.
    Vadalouca A, Moka E, Argyra E, Sikioti P, Siafaka I (2008) Opioid rotation in patients with cancer: a review of the current literature. J Opioid Manag 4:213–250CrossRefGoogle Scholar
  16. 16.
    González-Barboteo MDJ, Alentorn MD, Manuel FAC et al (2014) Effectiveness of opioid rotation in the control of cancer pain: the ROTODOL Study. J Opioid Manag 10:395–403CrossRefGoogle Scholar
  17. 17.
    Bouhassira D, Attal N, Alchaar H, Boureau F, Brochet B, Bruxelle J, Cunin G, Fermanian J, Ginies P, Grun-Overdyking A, Jafari-Schluep H, Lantéri-Minet M, Laurent B, Mick G, Serrie A, Valade D, Vicaut E (2005) Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain 114:29–36CrossRefGoogle Scholar
  18. 18.
    Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G, Science Committee of the Association for Palliative Medicine of Great Britain and Ireland (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338CrossRefGoogle Scholar
  19. 19.
    Tamburini M, Rosso S, Gamba A, Mencaglia E, de Conno F, Ventafridda V (1992) A therapy impact questionnaire for quality-of-life assessment in advanced cancer research. Ann Oncol 3:565–570CrossRefGoogle Scholar
  20. 20.
    Caraceni A, Et A (2012) Use of opioids analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012:e58–e68CrossRefGoogle Scholar
  21. 21.
    Mercadante S, Valle A, Porzio G, Fusco F, Aielli F, Adile C, Casuccio A, Home Care—Italy Group (2013) Opioid switching in patients with advanced cancer followed at home. A retrospective analysis. J Pain Symptom Manag 45:298–304CrossRefGoogle Scholar
  22. 22.
    Lawlor PG, Turner KS, Hanson J, Bruera ED (1998) Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 82:1167–1173CrossRefGoogle Scholar
  23. 23.
    Reddy A, Yennurajalingam S, Pulivarthi K, Palla SL, Wang X, Kwon JH, Frisbee-Hume S, Bruera E (2013) Frequency, outcome, and predictors of success within 6 weeks of an opioid rotation among outpatients with cancer receiving strong opioids. Oncologist 18:212–220CrossRefGoogle Scholar
  24. 24.
    Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, White RE, Witter J, Zavisic S (2008) Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain 9:105–121CrossRefGoogle Scholar
  25. 25.
    De Conno F, Groff L, Brunelli C et al (1996) Clinical experience with oral methadone administration in the treatment of pain in 196 advanced cancer patients. J Clin Oncol 14:2836–2842CrossRefGoogle Scholar
  26. 26.
    Holzer P, Ahmedzai SH, Niederle N et al (2009) Opioid-induced bowel dysfunction in cancer-related pain: causes, consequences, and a novel approach for its management. J Opioid Manag 5:145–151CrossRefGoogle Scholar
  27. 27.
    Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation (2009) Establishing “best practices” for opioid rotation: conclusions of an expert panel. J Pain Symptom Manag 38:418–425CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pain and Palliative Care Research Unit, Oncology DepartmentMario Negri Institute for Pharmacological Research IRCCSMilanItaly
  2. 2.Methodology for Clinical Research Laboratory, Oncology DepartmentMario Negri Institute for Pharmacological Research IRCCSMilanItaly
  3. 3.Palliative Care and Pain Therapy UnitASST Nord Milano, E. Bassini HospitalCinisello BalsamoItaly

Personalised recommendations